Used for biochemical studies, to prevent the prothrombin into thrombin.
用于生化研究，防止凝血酶原转变成凝血酶。
Prothrombin G20210A mutation can lead to plasma prothrombin level increase.
凝血酶原基因g20210a突变，可导致血浆凝血酶原水平升高。
Results No prothrombin gene G20210A mutation was found in both patients and controls.
结果所有受检者均未发现凝血酶原G20210A基因突变。
Patients with hypoproteinemia or prolonged prothrombin time (PT) were often accompanied by hypocalcemia.
低蛋白血症和PT延长的病例伴有低血钙较常见。
Objective: To study the relationship between prothrombin coagulative activity and the prognosis of patients with liver cirrhosis.
目的：研究凝血酶原活性与肝硬化病人预后的关系。
The majority of patients with ascites due to cirrhosis have prolongation of the prothrombin time and some degree of thrombocytopenia.
大多数肝硬化腹水的患者凝血酶原时间延长并有一定程度的血小板减少。
However, there was no significant difference in the total bilirubin and prothrombin time in either group during the observation periods.
然而，观察期间在总胆红素和凝血酶原时间方面两组之间没有显著差异。
Objective To evaluate the treatment of plasma exchange(PE) in patients with chronic severe hepatitis based on prothrombin activity(PTA).
目的探讨根据凝血酶原活动度（PTA）预测重型肝炎高胆红素血症行血浆置换的临床疗效。
The prothrombin time(PT) and the active partial thromboplastin time(APTT) were measured by the ACL- 200 antomatic blood agglutination instrument.
用ACL-200型血液凝集仪测定大鼠凝血酶原时间（PT）和部分凝血活酶时间（APTT）。
Objective:To prepare a monoclonal antibody against prothrombin fragment 1+2(F1+2) and study its diagnostic effect in patients with thromboembolism.
前言： 目的：自制凝血酶原片段F1+2单克隆抗体，探讨其在血栓性疾病中的诊断作用。
Objective: to monitor the curative effect of oral warfarin for the patients after heart mechanical valve displacement by the prothrombin time (PT).
目的评价采用凝血酶原时间(PT)监测心脏机械型瓣膜置换术后患者口服华法林治疗效果的意义。
There was no significant difference in platelet count, plasma prothrombin time and plasma viscosity between treatment group and control group ( P > 0.05) .
治疗组血小板计数、凝血酶原时间及血浆黏度变化与对照组相似（P>0.05）。
Technical conditions for adsorption and separation of prothrombin complex concentrates from human plasma with CG-6 macroporous anion-exchange resin were optimized.
优化了CG - 6型大孔阴离子交换树脂从人血浆中吸附和分离凝血酶原复合物的工艺条件。
[Packaging] Borosilicate glass vial, sealed with bromobutyl rubber stopper, packaging of 1 set per carton. 1 set contains a vial of human prothrombin complex, and solution.
硼硅玻璃模制注射剂瓶、溴化丁基橡胶塞包装。1套/盒。 1套包含人凝血酶原复合物1瓶，人凝血酶原复合物溶解液1瓶。
Objective To explore the clinical significance of platelet, prothrombin time , activated partial thromboplastin time , thrombin time , plasma fibrinogen for parturient women.
目的探讨临产孕妇血小板、凝血酶原时间、活化部分凝血活酶时间、凝血酶时间、纤维蛋白原检测的临床意义。
Purpose to establish the preparation procedure of human prothrombin complex concentrate (PCC) by using two-step gel chromatography to obtain high purity and high security product.
目的应用两步凝胶色谱法制备高纯度、高安全性的人凝血酶原复合物(PCC)制剂。
Plasma prothrombin time (PT), activate part plasma prothrombin time (APTT), prothrombin time (TT) , fibrinogen (FIB) the level of fasting blood glucose (GLU) are tested separately.
分别测定血浆凝血酶原时间（PT）、活化部分凝血酶原时间（APTT）、凝血酶时间（TT），纤维蛋白原（FIB）、血清空腹血糖（GLU）水平。
Conclusion: Combination of cryoprecipitate and prothrombin complex concentrate for traumatic hemorrhage has better effects than cryoprecipitate or prothrombin complex concentrate alone.
结论：联合应用冷沉淀与凝血酶原复合物在创伤性失血患者治疗中，联合输注组比单独输注组疗效更显著。
Objectives: Using normal plasmas and criterion plasmas to establish a kind of accurate and feasible method that could measure international normalized ratio (INR) of prothrombin time (PT).
目的：利用正常血浆和定标血浆，建立一种准确可靠、易于实验室开展的凝血酶原时间国际标准化比值检测方法。
Objective to investigate the clinical significance of detecting albumin (alb) plasma prothrombin coagulative time (PT), total bilirubin (TBIL) and total bile acid (TAB) on liver cirrhosis.
目的探讨肝硬化指标白蛋白(ALB)，凝血酶原时间(PT)，总胆红素(TBIL)，总胆汁酸(TBA)等四项指标对肝硬化诊断的临床意义。
Purpose: the purpose of this study is to prepare prothrombin complex concentrate (PCC) conjugated anionic lipid microbubbles and to assess the physiochemical properties of the microbubbles.
目的：制备结合凝血酶原复合物(PCC)的阴离子脂膜微泡，评价微泡的理化性质。
Objective To investigate the relationship between serum cholinesterase (CHE), prothrombin activity (PTA) and the clinical type, disease condition and prognosis in the viral hepatitis patients.
目的研究血清胆碱酯酶(CHE)、凝血酶原活动度(PTA)与病毒性肝炎临床分型、病情及预后之间的关系。
Therefore, to the reliability and comparability of the test, we believe that our domestic prothrombin reagents should be marked with accurate ISI value and INR should be used as PT report form.
为使PT结果具备可比性和可信性，我国的凝血活酶试剂应有准确ISI值标定。并推行以INR作为PT测定报告形式。
Objective: To explore clinical significance of detecting prothrombin time (PT), the activated partial thromboplastin time (APTT), thrombin time (TT), plasma fibrinogen (fib) for parturient women.
目的：探讨检测临产孕妇凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)的临床意义。
The adsorption behaviors and adsorption isothermals of total proteins and prothrombin complex concentrates and the effect factors on activity of prothrombin complex concentrates were investigated.
考察了其对血浆中总蛋白和凝血酶原复合物的吸附情况及吸附等温线，以及影响凝血酶原复合物活性的因素。
Objective To investigate the effects of different storage temperatures on anticoagulated blood hemagglutination tests, including prothrombin time(PT), and activated partial thromboplastin time(APTT).
目的探讨不同的抗凝血体外贮存条件对凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）的影响。
Laboratory: increase Prothrombin time (PT).
实验室检查：凝血酶原时间(PT)延长。
Methods Prothrombin fragments 1 and 2 (F1+2), fibrinopeptide A (FPA), soluble fibrin monomer complex(SFMC) were examined by enzyme linked immunoassay(ELISA);
方法采用酶联免疫分析法测定凝血酶原片段1+2 （F1+2 ）、纤维蛋白肽A（FPA）、可溶性纤维蛋白单体复合物（SFMC） ；
Methods Prothrombin fragments 1 and 2 (F1+2), fibrinopeptide A (FPA), soluble fibrin monomer complex(SFMC) were examined by enzyme linked immunoassay(ELISA);
方法采用酶联免疫分析法测定凝血酶原片段1+2 （F1+2 ）、纤维蛋白肽A（FPA）、可溶性纤维蛋白单体复合物（SFMC） ；
应用推荐